Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Low Float!
Got some at these low prices! Ready for next week!
IB borrow fee data:
Fee, Available, Updated
111.7 %, 100,000, 2021-12-31 11:45:03
CNTX could run hard with some good news, IB borrow Fee = 103.4 % as of 2021-12-29 16:45:03
Time to ring the register!! Cha Ching!
COUV - sleeping giant is about to be awakened!
quietly ringing the register!
1.9M shares traded, not too shabby!
Just need MM to push it to $1 when CE is removed!
...AND... Shorts in control again!
Would be nice to see the squeezing action tomorrow! It was traded more than 10x of the float on the last crazy volume movement.
Going QB Exchange after Grey Market!!!!!
Awesome! Can't wait to see COUV on the QB Exchange.
Sorry I misspoke. I picked up a good chunk of COUV in March average .10
I've picked up a healthy chunk of COUV in hopes of Form 211 and Pink current soon!
I recently picked up a good amount of COUV at these low prices. Hopefully the fog is cleared up soon.
$$$$$ out!
Your questions are legit and respected.
Those were just my opinions and reasons to sell. I've been holding CNNA too long - about 2 years.... dumping it for a 50%+ gain doesn't hurt. I could always get back in... anytime.
On top of dilution of 1B is imminent, below were the last pieces of information why I dumped all my shares yesterday!
No product!
We do not manufacture any of the products that we currently offer. Consequently, we have no control over manufacturing practices at the suppliers from whom we procure the products we offer...
A one man show!
We have one employee, our President, Jason Black. Mr. Black will devote full time to us. As of January 4, 2021, we had no full-time employees who were not an executive officer of the Company, and no part-time employees.
https://www.sec.gov/Archives/edgar/data/1368620/000168316821000003/cnna_1a-a5.htm
It appears Mr Black has been renting a room from The Soil King Garden Center for his previous company (IGEX) and CNNA.
320 Santana Drive, #C, Cloverdale, CA 95425
https://www.google.com/maps/place/320+Santana+Dr+C,+Cloverdale,+CA+95425/@38.785979,-123.0105102,17z/data=!3m1!4b1!4m5!3m4!1s0x808400bce0e47ec9:0xae656ac82aae2c24!8m2!3d38.7859748!4d-123.0083215
https://www.marketwatch.com/investing/stock/igex/company-profile?pid=178673933
Burning midnight oil. Enjoy the information below:
Total shares authorized: 1,998,000,000 as of date: 09/16/2020
Total shares outstanding: 205,000,186 as of date: 11/30/2020
Number of shares in the Public Float: 127,421,789 as of date: 11/30/2020
Total number of shareholders of record: 17 as of date: 11/30/2020
https://drive.google.com/file/d/1VjsJyxJQx1KZTCnwG1WG6rwJCq71sZRq/view?usp=sharing
Summary: Using the information below, we could find the property’s parcel #, the current tax bill status, and the address: 2511 CONNIE DR, SACRAMENTO, CA 95815. This address used to be Kim's Pottery & Beyond Landscaper. Now it’s being renovated for EPC- Cannabis, Permit# COM-2019003.
Permit #COM-2019003 screenshot from:
Permit issued for remaining improvements on $CNNA delivery dispensary project. Additional updates to follow. pic.twitter.com/n0k7rxLEh7
— CNNA (@CNNA_OTC) February 22, 2021
This will be relevant for $CNNA very soon. A few details to finalize before announcements. pic.twitter.com/MjJMxAZJM4
— CNNA (@CNNA_OTC) May 26, 2020
Here are some floor plans on the cannabis delivery from the original permit application. It's a great building with immediate access to the freeway. Very excited about this $CNNA endeavor. pic.twitter.com/zl1IhhHM2s
— CNNA (@CNNA_OTC) June 15, 2020
IRVINE, Calf.--(BUSINESS WIRE)-- Allied Esports Entertainment, Inc. (NASDAQ: AESE) (the “Company”), a global esports entertainment company, confirmed that it received an unsolicited proposal from Bally’s Corporation (“Bally’s”) to acquire all of the outstanding equity interests of the Company for a total consideration of $100 million , payable, at the Company’s option, in cash, Bally’s capital stock, or a combination of both. The Bally’s proposal would require the Company to terminate its previously announced agreement with Element Partners, LLC (“Element”) to sell all of the equity interests of Club Services, Inc. (“CSI”), an indirect wholly-owned subsidiary of the Company that directly or indirectly owns the Company’s poker-related business and assets, including the entities comprising the World Poker Tour® (“World Poker Tour,” or “WPT®”), for consideration totaling $78,250,000 .
The Company’s Board of Directors, consistent with its duties and the Company’s obligations under its existing agreement with Element, will evaluate Bally’s proposal in due course. The Company and Element continue to discuss potential updates to the current terms of their agreement.
There can be no assurance that the Company will enter into a definitive agreement with Bally’s or consummate any transaction with Bally’s.
At this time, the Company’s Board of Directors continues to recommend to the Company’s stockholders the approval of the transaction with Element. The Company has filed with the SEC and mailed to its stockholders a Consent Solicitation Statement in connection with the Element transaction. If approved by the Company’s stockholders, and subject to satisfaction of other closing conditions, the transaction with Element would be expected to close on or about March 30, 2021 .
The Company will file a current report on Form 8-K with the Securities and Exchange Commission (the “SEC”) containing a copy of Bally’s proposal. The current report on Form 8-K will be available on the SEC’s website, http://www.sec.gov. Stockholders are urged to read the proposal.
About World Poker Tour
World Poker Tour (WPT) is the premier name in internationally televised gaming and entertainment with brand presence in land-based tournaments, television, online, and mobile. Leading innovation in the sport of poker since 2002, WPT ignited the global poker boom with the creation of a unique television show based on a series of high-stakes poker tournaments. WPT has broadcast globally in more than 150 countries and territories, and is currently producing its 18th season, which airs on FOX Sports Regional Networks in the United States . Season XVIII of WPT is sponsored by ClubWPT.com. ClubWPT.com is a unique online membership site that offers inside access to the WPT, as well as a sweepstakes-based poker club available in 43 states and territories across the United States , Australia , Canada , France and the United Kingdom . WPT also participates in strategic brand license, partnership, and sponsorship opportunities. For more information, go to WPT.com. WPT Enterprises Inc. is a subsidiary of Allied Esports Entertainment, Inc.
About Allied Esports Entertainment (AESE)
Allied Esports Entertainment (NASDAQ: AESE) is a global esports entertainment venture dedicated to providing transformative live experiences, multiplatform content and interactive services to audiences worldwide through its strategic fusion of two powerful entertainment brands: Allied Esports and the World Poker Tour (WPT). On January 19, 2021 , AESE entered into a Stock Purchase Agreement to sell the equity interests that own WPT to Element Partners, LLC once all applicable shareholder and regulatory consents have been obtained, and the other conditions to closing have been satisfied (the “Proposed Transaction”).
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to future results, strategy and plans of Allied Esports Entertainment, Inc. and the World Poker Tour (collectively, the “Companies”) (including certain projections and business trends, and statements, which may be identified by the use of the words “plans”, “expects” or “does not expect”, “estimated”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “projects”, “will” or “will be taken”, “occur” or “be achieved”). Forward-looking statements are based on the opinions and estimates of management of the Companies as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. For example, the Bally’s proposal may not result in a definitive agreement for an alternative transaction. Other risks and uncertainties include, but are not limited to, each Company’s respective revenues and operating performance, general economic conditions, industry trends, legislation or regulatory requirements affecting the business in which it is engaged, management of growth, its business strategy and plans, the result of future financing efforts and its dependence on key personnel, and the ability to retain key personnel. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as of the date hereof, and no Company undertakes any obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. With respect to the Proposed Transaction, these factors include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the Stock Purchase Agreement or could otherwise cause the Proposed Transaction to fail to close; the outcome of any legal proceedings that may be instituted against us following the announcement of the Proposed Transaction; the inability to complete the Proposed Transaction, including due to failure to obtain approval of AESE’s stockholders or other conditions to closing; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Proposed Transaction; a change in our plans to retain the net cash proceeds from the Proposed Transaction; our inability to enter into one or more future acquisition or strategic transactions using the net proceeds from the Proposed Transaction; an event or condition that results in our not fully participating in the future revenues of Buyer (as contemplated by the Stock Purchase Agreement); and a decision not to pursue strategic options for the esports business. Further information on potential factors that could affect our business is described under “Risk Factors” in AESE’s Consent Solicitation Statement dated February 1, 2021 , filed with the SEC on February 2, 2021 .
No Offer or Solicitation
This communication is for informational purposes only and is neither an offer to sell or purchase, nor the solicitation of an offer to buy or sell any securities, nor is it a solicitation of any vote, consent, or approval in any jurisdiction pursuant to or in connection with the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Important Additional Information Has Been Filed With the SEC
AESE has filed with the SEC and mailed to its stockholders the Consent Solicitation Statement in connection with the Proposed Transaction. The Consent Solicitation Statement contains important information about the Companies, the Proposed Transaction and the Stock Purchase Agreement. Investors and stockholders are urged to read the Consent Solicitation Statement carefully before making any decision to invest or consent to the Proposed Transaction.
Investors and stockholders will be able to obtain free copies of the Consent Solicitation Statement and other documents filed by AESE with the SEC through the website maintained by the SEC at www.sec.gov. AESE encourages all stockholders of record on January 28, 2021 , whom have not yet completed a stockholder consent to approve the Proposed Transaction, to do so by April 9, 2021 at 5:00 p.m. (Eastern Time) . Stockholders who have any questions or require any assistance with completing a stockholder consent or who do not have the required materials, may contact AESE’s solicitor, Regan & Associates, Inc. , by telephone (toll-free within North America ) at 1-800-737-3426.
Participants in the Solicitation
In addition to Regan & Associates, Inc. , AESE, its directors and executive officers may be deemed to be participants in the solicitation of consents with respect to the Proposed Transaction. Information regarding AESE’s directors and executive officers and their ownership of AESE shares is contained in AESE’s Amended Annual Report on Form 10-K/A for the year ended December 31, 2019 and its definitive consent solicitation statement for the Proposed Transaction which was filed with the SEC on February 2, 2021 , and is supplemented by other public filings made, and to be made, with the SEC . AESE’s directors and executive officers beneficially own approximately 6.8% of AESE’s common stock. Investors and stockholders may obtain additional information regarding the direct and indirect interests of AESE and its directors and executive officers with respect to the Proposed Transaction by reading the proxy statement and other filings referred to above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005230/en/
Investor Contact: Lasse Glassen Addo Investor Relations
SAN FRANCISCO and TORONTO , March 03, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc. ) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into a Strategic Collaboration Agreement (the Collaboration Agreement”) with the Salzman Group, Ltd. (“Salzman Group”), and is in the process of entering into similar agreements with other companies, to expedite the development of the Company’s breakthrough nitric oxide-releasing compound, R-107.
Strategic Collaboration with Salzman Group
To conserve capital and expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies for the manufacture of R-107, and for the design and completion of clinical studies to demonstrate the safety and efficacy of R-107 in the treatment of COVID-19, influenza, and other viral infections.
Under the Collaboration Agreement, Salzman Group will make available to Claritas the full capabilities of Salzman Group , including its expertise in working with nitric oxide and nitric oxide releasing compounds. Key members of the Salzman Group include the following research scientists, each of whom has deep expertise with nitric oxide:
Andrew Salzman , M.D., Chairman of Salzman Group , was, in 1990, the first physician to administer inhaled nitric oxide to a human patient. Dr. Salzman received his undergraduate degree from Yale University and his medical degree from Harvard Medical School . Over the last 25 years, Dr. Salzman has received funding for 135 NIH , DARPA , and BARDA grants totaling $160 million and venture capital funding of $100 million . This funding has supported research and drug development activities in the field of nitric oxide, resulting in 200 scientific publications and 50 patents, spanning work in ischemia-reperfusion injury, intestinal mucosal biology, pulmonary arterial hypertension, autoimmune disease, infectious disease, and mechanisms of pro-inflammatory gene expression. Dr. Salzman has taken 12 of his pharmaceutical inventions from the bench into the clinic.
Garry Southan , Ph.D., Drug Development Consultant, trained under Nobel Laureate John Vane in the biology and chemistry of nitric oxide; was the Principal Investigator on multiple federal and private R&D projects to develop novel nitric oxide therapies; and is the inventor of the first selective inducible nitric oxide synthase inhibitor. Dr. Southan has worked with Dr. Salzman for 25 years, moving 12 small molecules from the preclinical to clinical phases throughout his career.
Prakash Jagtap , Ph.D., Medicinal Chemistry Consultant, inventor of the R-107 molecule that led to an award of a USD $84.9 million BARDA contract to develop R-107 as an antidote to chlorine inhalation lung injury. Dr. Jagtap has over 50 patents co-invented with Dr. Salzman , and has co-developed over 8 small molecules with him over his career.
Yousif Sahly , Ph.D., Salzman Group’s Director of Quality Control, trained at Massachusetts Institute of Technology and has over 25 years of experience in small molecule drug development. Dr. Sahly was the former Director of Metabolism and Pharmacokinetics at Pfizer and Director of Analytical Research and Development at Teva. He oversaw all analytical work on innovative drug development at Teva. Dr. Sahly has led the GMP analytical and GLP bioanalytical studies carried out on R-107 since 2018.
Gali Guzikevich, Ph.D., Salzman Group’s Director of Quality Assurance, trained at the Weizmann Institute of Science and served as the Director of Quality Assurance and Regulatory Affairs at Teva for over 15 years. Dr. Guzikevich manages the Quality Assurance of both the GMP and GLP Salzman Group laboratories, where R-107 studies have been performed.
Amos Rosenthal , Ph.D., Salzman Group’s Head of Chemistry, earned his doctoral degree at the Swiss Federal Institute of Technology and his post-doctoral fellowship at Université Toulouse III - Paul Sabatier . Dr. Rosenthal has published several articles in peer-reviewed journals, including in Science. Dr. Rosenthal is leading the GMP process scale-up development of R-107 from gram to kilogram, for commercial production.
Iris Maimon , Ph.D., Salzman Group’s Director of Drug Development, earned her doctoral degree and post-doctoral degree from the Weizmann Institute of Science . Dr. Maimon’s expertise is in the field of acute lung injury and pulmonary hypertension pharmacology. She has been leading the R-107 preclinical development program since its inception.
Salzman Group will also provide a platform of services, including expertise in the manufacture of R-107, design of clinical studies, and consulting services in connection with Claritas’ interactions with regulatory bodies in the USA , Australia , the UK , and the EU.
The significant benefits that Claritas will realize from this collaboration include:
Access to Salzman Group’s research scientists and drug development experts on a part-time basis, which will provide a lower cost structure than the Company would incur by hiring its own team of such experts;
Continuation of in-process work with the same team of Salzman Group researchers that invented R-107, and developed the know-how for the manufacturing process that will enable Claritas to produce R-107 quickly and at scale, without the delays that would result from of transferring this know-how to a third-party contract manufacturer; and
Continuation of work with the same team that successfully completed the preclinical work required to advance R-107 into human clinical testing.
“Nitric oxide has a well-documented safety profile and has been demonstrated to be effective against a wide variety of viruses,” stated Dr. Andrew Salzman , Chairman of the Salzman Group . “Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas, and must be administered by inhalation therapy. Our group has worked to design a nitric oxide releasing compound to overcome these issues. This multi-year effort was successful, and resulted in the invention of R-107, which can be administered orally as a capsule, or nasally through use of a nasal spray, or by injection.”
Dr. Salzman continued, “We are delighted to be working with Claritas to develop R-107, not only as a therapy for vaccine-resistant COVID-19 infection, but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.”
Future collaborations with CMAX and PCI Pharma Services
Claritas will initiate human clinical studies in Australia in order to receive the 43% R&D tax credit refund that is provided by the Australian government to encourage companies to engage in research and development work benefiting Australia .
The Phase 1 clinical study of intramuscular R-107 will be conducted at CMAX, a clinical contract research organization located at Royal Adelaide Hospital in Australia . Claritas is in discussions with CMAX regarding a strategic collaboration, under which CMAX will use best efforts to expedite the completion of the Phase 1 study. Claritas is also engaged in similar discussions with PCI Pharma Services , an Australian company that will provide formulation and logistical services in connection with the Phase 1 study.
Professor Salvatore Cuzzocrea , President of the University of Messina and former President of the European Shock Society is working with Salzman Group and Claritas, and has read and approved of the scientific disclosure in this news release. Professor Cuzzocrea has deep expertise regarding the medical use of nitric oxide and nitric oxide donors, and has published more than 600 papers on nitric oxide. He has conducted research and experiments with nitric oxide and nitric oxide donors since 1994, and worked closely as an advisor with the Salzman Group team that designed and invented R-107.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
About Claritas Pharmaceuticals Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives.
Website Home: https://claritaspharma.com/
News and Insights: https://claritaspharma.com/news/
Investors: https://claritaspharma.com/investors
Cautionary Statements Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange ) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives, and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavorable results. Claritas undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Claritas believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Claritas’ control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Contact Information Robert Farrell President, CEO (888) 861-2008 info@claritaspharma.com
To me, this statement is saying we're not going to be in sub-penny soon... I'm thinking of 0.50 to 1.00+
Stated CEO, Jason Black: "A year ago the idea of doing a reverse split was furthest from my mind. But, in recent months, as the Company finds itself networking and negotiating with multi-million dollar companies and conglomerates, it became apparent that the optics of trading in the sub pennies was becoming an obstacle in negotiations. I believe the current capital structure will serve the Company and its shareholders much better in the long run. I'd like to thank shareholders for their support during this transition."
Amazing!
Explosive Volume!
Dollar land? "...as the Company finds itself networking and negotiating with multi-million dollar companies and conglomerates, it became apparent that the optics of trading in the sub pennies was becoming an obstacle in negotiations..."
WOW!... "the sub pennies was becoming an obstacle"...
Stated CEO, Jason Black: "A year ago the idea of doing a reverse split was furthest from my mind. But, in recent months, as the Company finds itself networking and negotiating with multi-million dollar companies and conglomerates, it became apparent that the optics of trading in the sub pennies was becoming an obstacle in negotiations. I believe the current capital structure will serve the Company and its shareholders much better in the long run. I'd like to thank shareholders for their support during this transition."
Yes, it could be one of the hottest SPAC mergers.
Get your tickets before the show begins...
It's Moving!
This could fly BIG TIME if we get some sort of confirmation of the SPAC merger.
$$$ Zoom Zoom $$$
I'm ready for more action!
$HCAC is ready to fly
EVUS is getting good support @.0015. If it breaks.0017 - time to blast off again!
We just need NEWS!
Nice 30Mil support @.0012
$EVUS - IT's a live again!
Wow many times X OS traded in the last 2 days. Wonder what the float is?
Boom! my truck got lighter now...